Mosanna Therapeutics

Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.